U.S. government researchers found on November 22, 2024, that montelukast, sold under the brand name Singulair and originally by Merck & Co., may be linked to serious mental health problems for some patients.
A scientific presentation reviewed by Reuters indicated that the drug attaches to multiple brain receptors critical to psychiatric functioning. Singulair was a blockbuster product for Merck after its launch in 1998.
This finding could lead to increased regulatory scrutiny and potential legal challenges regarding the drug's safety profile. The association with mental health issues for a widely prescribed medication is a significant concern.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.